The study showed that nondisruptive TP53 mutations are related to poor survival (17.8 months vs. 28.4 months) compared to TP53 wild-type stage IIIB–IV EGFR-mutated NSCLC patients, and multivariate analyses suggested that nondisruptive TP53 mutations were independent prognostic factors associated with a shorter OS (26). This evidence concerns the gene EGFR and non-small cell lung carcinoma.